Incyte (INCY)
(Delayed Data from NSDQ)
$65.87 USD
+0.50 (0.76%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $65.87 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Price, Consensus and EPS Surprise
INCY 65.87 +0.50(0.76%)
Will INCY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INCY
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
INCY or MYGN: Which Is the Better Value Stock Right Now?
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
Other News for INCY
Most shorted S&P 500 stocks in June
Incyte to Report Second Quarter Financial Results
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Analyst Expectations For Incyte's Future